{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:28:33Z","timestamp":1793035713165,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Otsuka Pharmaceutical Europe Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12882-017-0804-2","type":"journal-article","created":{"date-parts":[[2018,2,13]],"date-time":"2018-02-13T08:09:54Z","timestamp":1518509394000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): the ADPKD Outcomes Model"],"prefix":"10.1186","volume":"19","author":[{"given":"Phil","family":"McEwan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley","family":"Bennett Wilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert C. M.","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjarne","family":"\u00d8rskov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Sandford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Scolari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Cristina V.","family":"Cabrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Walz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"O\u2019Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,13]]},"reference":[{"key":"804_CR1","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/S0140-6736(15)60907-2","volume":"385","author":"AC Ong","year":"2015","unstructured":"Ong AC, Devuyst O, Knebelmann B, Walz G, ERA-EDTA Working Group for Inherited Kidney Diseases. Autosomal dominant polycystic kidney disease: the changing face of clinical management. Lancet. 2015;385:1993\u20132002.","journal-title":"Lancet"},{"issue":"Suppl 4","key":"804_CR2","doi-asserted-by":"publisher","first-page":"iv15","DOI":"10.1093\/ndt\/gfu017","volume":"29","author":"EM Spithoven","year":"2014","unstructured":"Spithoven EM, Kramer A, Meijer E, Orskov B, Wanner C, Abad JM, et al. Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival\u2014an analysis of data from the ERA-EDTA registry. Nephrol Dial Transplant. 2014;29(Suppl 4):iv15\u201325.","journal-title":"Nephrol Dial Transplant"},{"key":"804_CR3","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1681\/ASN.2013111184","volume":"25","author":"RW Schrier","year":"2014","unstructured":"Schrier RW, Brosnahan G, Cadnapaphornchai MA, Chonchol M, Friend K, Gitomer B, et al. Predictors of autosomal dominant polycystic kidney disease progression. J Am Soc Nephrol. 2014;25:2399\u2013418.","journal-title":"J Am Soc Nephrol"},{"key":"804_CR4","doi-asserted-by":"publisher","unstructured":"Willey CJ, Blais JD, Hall AK, Krasa HB, Makin AJ, Czerwiec FS. Prevalence of autosomal dominant polycystic kidney disease in the European Union. Nephrol Dial Transplant. 2016; \n                    https:\/\/doi.org\/10.1093\/ndt\/gfw240\n                    \n                  .","DOI":"10.1093\/ndt\/gfw240"},{"key":"804_CR5","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1093\/ndt\/gfu087","volume":"29","author":"C Shaw","year":"2014","unstructured":"Shaw C, Simms RJ, Pitcher D, Sandford R. Epidemiology of patients in England and Wales with autosomal dominant polycystic kidney disease and end-stage renal failure. Nephrol Dial Transplant. 2014;29:1910\u20138.","journal-title":"Nephrol Dial Transplant"},{"key":"804_CR6","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1038\/ki.2014.120","volume":"86","author":"EM Spithoven","year":"2014","unstructured":"Spithoven EM, Kramer A, Meijer E, Orskov B, Wanner C, Caskey F, et al. Analysis of data from the ERA-EDTA registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease. Kidney Int. 2014;86:1244\u201352.","journal-title":"Kidney Int"},{"key":"804_CR7","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1053\/j.ajkd.2013.08.017","volume":"63","author":"DC Miskulin","year":"2014","unstructured":"Miskulin DC, Abebe KZ, Chapman AB, Perrone RD, Steinman TI, Torres VE, et al. Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study. Am J Kidney Dis. 2014;63:214\u201326.","journal-title":"Am J Kidney Dis"},{"key":"804_CR8","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/ndt\/gfv456","volume":"31","author":"RT Gansevoort","year":"2016","unstructured":"Gansevoort RT, Arici M, Benzing T, Birn H, Capasso G, Covic A, et al. Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA working groups on inherited kidney disorders and European renal best practice. Nephrol Dial Transplant. 2016;31:337\u201348.","journal-title":"Nephrol Dial Transplant"},{"key":"804_CR9","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1681\/ASN.2013101138","volume":"26","author":"MV Irazabal","year":"2015","unstructured":"Irazabal MV, Rangel LJ, Bergstralh EJ, Osborn SL, Harmon AJ, Sundsbak JL, et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol. 2015;26:160\u201372.","journal-title":"J Am Soc Nephrol"},{"key":"804_CR10","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12882-015-0114-5","volume":"16","author":"C Woon","year":"2015","unstructured":"Woon C, Bielinski-Bradbury A, O\u2019Reilly K, Robinson P. A systematic review of the predictors of disease progression in patients with autosomal dominant polycystic kidney disease. BMC Nephrol. 2015;16:140.","journal-title":"BMC Nephrol"},{"key":"804_CR11","unstructured":"European Medicines Agency. European public assessment report summary for the public: Jinarc (tolvaptan). 2016. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/002788\/WC500187924.pdf\n                    \n                  . Accessed 30 Nov 2016."},{"key":"804_CR12","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367:2407\u201318.","journal-title":"N Engl J Med"},{"key":"804_CR13","unstructured":"National Institute for Health and Care Excellence. Chronic kidney disease in adults: assessment and management. Clinical guideline [CG182]. 2015. \n                    https:\/\/www.nice.org.uk\/guidance\/cg182\n                    \n                  . Accessed 30 Mar 2017."},{"key":"804_CR14","doi-asserted-by":"crossref","unstructured":"Venables WN, Ripley BD. Modern Applied Statistics with S. 4th ed. New York: Springer; 2002.","DOI":"10.1007\/978-0-387-21706-2"},{"key":"804_CR15","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604\u201312.","journal-title":"Ann Intern Med"},{"key":"804_CR16","unstructured":"UK Office for National Statistics. National life tables, UK: 2013\u20132015. 2016. \n                    https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/lifeexpectancies\/bulletins\/nationallifetablesunitedkingdom\/20132015\n                    \n                  . Accessed 22 Mar 2017."},{"key":"804_CR17","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1046\/j.1523-1755.2003.00185.x","volume":"64","author":"AB Chapman","year":"2003","unstructured":"Chapman AB, Guay-Woodford LM, Grantham JJ, Torres VE, Bae KT, Baumgarten DA, et al. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): the consortium for radiologic imaging studies of polycystic kidney disease (CRISP) cohort. Kidney Int. 2003;64:1035\u201345.","journal-title":"Kidney Int"},{"key":"804_CR18","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1056\/NEJMoa054341","volume":"354","author":"JJ Grantham","year":"2006","unstructured":"Grantham JJ, Torres VE, Chapman AB, Guay-Woodford LM, Bae KT, King BF Jr, et al. Volume progression in polycystic kidney disease. N Engl J Med. 2006;354:2122\u201330.","journal-title":"N Engl J Med"},{"key":"804_CR19","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1402685","volume":"371","author":"RW Schrier","year":"2014","unstructured":"Schrier RW, Abebe KZ, Perrone RD, Torres VE, Braun WE, Steinman TI, et al. Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med. 2014;371:2255\u201366.","journal-title":"N Engl J Med"},{"key":"804_CR20","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1056\/NEJMoa1402686","volume":"371","author":"VE Torres","year":"2014","unstructured":"Torres VE, Abebe KZ, Chapman AB, Schrier RW, Braun WE, Steinman TI, et al. Angiotensin blockade in late autosomal dominant polycystic kidney disease. N Engl J Med. 2014;371:2267\u201376.","journal-title":"N Engl J Med"},{"key":"804_CR21","unstructured":"In Practice Systems Ltd. The Health Improvement Network (THIN). 2017. \n                    https:\/\/www.visionhealth.co.uk\/portfolio-items\/the-health-improvement-network-thin\/\n                    \n                  . Accessed 8 Jan 2018."},{"key":"804_CR22","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1681\/ASN.2015010016","volume":"27","author":"E Cornec-Le Gall","year":"2016","unstructured":"Cornec-Le Gall E, Audr\u00e9zet M-P, Rousseau A, Hourmant M, Renaudineau E, Charasse C, et al. The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2016;27:942\u201351.","journal-title":"J Am Soc Nephrol"},{"key":"804_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-3462-1","volume-title":"Regression Modeling Strategies","author":"F Harrell","year":"2001","unstructured":"Harrell F. Regression Modeling Strategies. New York: Springer; 2001."},{"key":"804_CR24","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1053\/j.ajkd.2010.11.029","volume":"57","author":"VE Torres","year":"2011","unstructured":"Torres VE, Meijer E, Bae KT, Chapman AB, Devuyst O, Gansevoort RT, et al. Rationale and design of the TEMPO (tolvaptan efficacy and safety in management of autosomal dominant polycystic kidney disease and its outcomes) 3-4 study. Am J Kidney Dis. 2011;57:692\u20139.","journal-title":"Am J Kidney Dis"},{"key":"804_CR25","unstructured":"Davis S, Stevenson M, Tappenden P, Wailoo A. NICE DSU Technical Support Document 15: Cost-effectiveness modelling using patient-level simulation. 2014. \n                    http:\/\/scharr.dept.shef.ac.uk\/nicedsu\/wp-content\/uploads\/sites\/7\/2016\/03\/TSD15_Patient-level_simulation.pdf\n                    \n                  . Accessed 28 Apr 2017."},{"key":"804_CR26","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.jval.2012.06.012","volume":"32","author":"JJ Caro","year":"2012","unstructured":"Caro JJ, Briggs AH, Siebert U, Kuntz KM. Modeling good research practices\u2014overview: a report of the ISPOR-SMDM modeling good research practices task force\u20131. Value Health. 2012;32:796\u2013803.","journal-title":"Value Health"},{"key":"804_CR27","unstructured":"National Institute for Health and Care Excellence. Tolvaptan for treating autosomal dominant polycystic kidney disease. Technology appraisal guidance [TA358]. 2015. \n                    https:\/\/www.nice.org.uk\/guidance\/ta358\n                    \n                  . Accessed 30 Nov 2016."},{"key":"804_CR28","unstructured":"Scottish Medicines Consortium. tolvaptan (Jinarc). 2016. \n                    https:\/\/www.scottishmedicines.org.uk\/SMC_Advice\/Advice\/1114_15_tolvaptan_Jinarc\n                    \n                  . Accessed 28 Apr 2017."},{"key":"804_CR29","unstructured":"European Commission. The 2015 Ageing Report: Economic and budgetary projections for the 28 EU Member States (2013\u20132060). 2015. \n                    http:\/\/ec.europa.eu\/economy_finance\/publications\/european_economy\/2015\/pdf\/ee3_en.pdf\n                    \n                  . Accessed 3 Jul 2017."},{"key":"804_CR30","unstructured":"European Medicines Agency. Qualification opinion: Total Kidney Volume (TKV) as a prognostic biomarker for use in clinical trials evaluating patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD). 2015. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Regulatory_and_procedural_guideline\/2015\/11\/WC500196569.pdf\n                    \n                  . Accessed 22 Mar 2017."},{"key":"804_CR31","unstructured":"Food and Drug Administration. Clinical Review of PKD Outcomes Consortium biomarker qualification submission. 2015. \n                    https:\/\/www.fda.gov\/downloads\/Drugs\/DevelopmentApprovalProcess\/DrugDevelopmentToolsQualificationProgram\/UCM458499.pdf\n                    \n                  . Accessed 22 Mar 2017."},{"key":"804_CR32","first-page":"511","volume":"17","author":"ER Ahmed","year":"2006","unstructured":"Ahmed ER, Tashkandi MA, Nahrir S, Maulana A. Retrospective analysis of factors affecting the progression of chronic renal failure in adult polycystic kidney disease. Saudi J Kidney Dis Transpl. 2006;17:511\u20135.","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"804_CR33","first-page":"235","volume":"26","author":"E De Almeida","year":"2007","unstructured":"De Almeida E, De Oliveira E, Lopes J, Almeida A, Lopes M, Prata M. Ambulatory blood pressure measurement in young normotensive patients with autosomal dominant polycystic kidney disease. Rev Port Cardiol. 2007;26:235\u201343.","journal-title":"Rev Port Cardiol"},{"key":"804_CR34","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/MNH.0b013e3283621510","volume":"22","author":"O Devuyst","year":"2013","unstructured":"Devuyst O, Torres VE. Osmoregulation, vasopressin, and cAMP signaling in autosomal dominant polycystic kidney disease. Curr Opin Nephrol Hypertens. 2013;22:459\u201370.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"804_CR35","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.bbadis.2011.03.002","volume":"1812","author":"YC Tan","year":"2011","unstructured":"Tan YC, Blumenfeld J, Rennert H. Autosomal dominant polycystic kidney disease: genetics, mutations and microRNAs. Biochim Biophys Acta. 2011;1812:1202\u201312.","journal-title":"Biochim Biophys Acta"},{"key":"804_CR36","doi-asserted-by":"publisher","first-page":"479","DOI":"10.2215\/CJN.09500911","volume":"7","author":"AB Chapman","year":"2012","unstructured":"Chapman AB, Bost JE, Torres VE, Guay-Woodford L, Bae KT, Landsittel D, et al. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2012;7:479\u201386.","journal-title":"Clin J Am Soc Nephrol"},{"key":"804_CR37","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1681\/ASN.2006080835","volume":"17","author":"PC Harris","year":"2006","unstructured":"Harris PC, Bae KT, Rossetti S, Torres VE, Grantham JJ, Chapman AB, et al. Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2006;17:3013\u20139.","journal-title":"J Am Soc Nephrol"},{"key":"804_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2054358117693355","volume":"4","author":"N Tangri","year":"2017","unstructured":"Tangri N, Hougen I, Alam A, Perrone R, McFarlane P, Pei Y. Total kidney volume as a biomarker of disease progression in Autosomal dominant polycystic kidney disease. Can J Kidney Health Dis. 2017;4:1\u20136.","journal-title":"Can J Kidney Health Dis"},{"key":"804_CR39","series-title":"Protocol no. 156\u201304-251. A phase 3, multi-center, double-blind, placebo-controlled, parallel-arm trial to determine long-term safety and efficacy of oral tolvaptan tablet regimens in adult subjects with autosomal dominant polycystic kidney disease","volume-title":"Amended clinical study report","author":"Otsuka Pharmaceutical Development & Commercialization Inc","year":"2013","unstructured":"Otsuka Pharmaceutical Development & Commercialization Inc. Amended clinical study report. Protocol no. 156\u201304-251. A phase 3, multi-center, double-blind, placebo-controlled, parallel-arm trial to determine long-term safety and efficacy of oral tolvaptan tablet regimens in adult subjects with autosomal dominant polycystic kidney disease. 2013."},{"key":"804_CR40","doi-asserted-by":"crossref","unstructured":"Thong KM, Ong AC. The natural history of autosomal dominant polycystic kidney disease: 30-year experience from a single centre. QJM. 2013;106:639-46.","DOI":"10.1093\/qjmed\/hct082"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-017-0804-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T00:30:38Z","timestamp":1550017838000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-017-0804-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,13]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["804"],"URL":"https:\/\/doi.org\/10.1186\/s12882-017-0804-2","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,13]]},"assertion":[{"value":"27 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article is based on previously conducted research, and does not involve any new studies of human or animal subjects performed by any of the authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ACMO, B\u00d8, RS, FS, M-CVC, and GW have received honoraria from Otsuka Pharmaceutical Europe Ltd. for serving on advisory board meetings and\/or lectures. PM and HBW are employees of HEOR Ltd., a company sponsored by Otsuka Pharmaceutical Europe Ltd. to build the model. KO and PR are employees of Otsuka Pharmaceutical Europe Ltd.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"37"}}